Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platformYu‐Qing Zhang, Thanh U. Barbie, Elliott J. Brea et al.|Cell Reports Medicine|2025Cited by 4
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J. Brea, Eric L. Smith, Simon Baldacci et al.|Cancer Immunology Research|2025Cited by 4
Figure_S1 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J. Brea, Eric L. Smith, Simon Baldacci et al.|Unknown|2025Cited by 0
Figure_S3 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J. Brea, Eric L. Smith, Simon Baldacci et al.|Unknown|2025Cited by 0
Figure_S2 from Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid TumorsElliott J. Brea, Eric L. Smith, Simon Baldacci et al.|Unknown|2025Cited by 0